Dhyani et al. have investigated 99mTc-tricarbonyl-labeled derivatives of 11ß-progesterone and 17α-testosterone for targeting progesterone (PR) and androgen receptors (AR), which are overexpressed in breast and prostate cancer, respectively [56,57]. This evidence concerns the gene AR and prostate carcinoma.